PHIO (Phio Pharmaceuticals) Shiller PE Ratio: (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHIO Phio Pharmaceuticals Corp PHIO
28 GF Score
Price $1.08
! 2 Warning Signs
View Full Analysis

What is Phio Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Phio Pharmaceuticals  (NAS:PHIO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Phio Pharmaceuticals Shiller PE Ratio Related Terms


Phio Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Phio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phio Pharmaceuticals Shiller PE Ratio Chart

Phio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Phio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PHIO vs KALA, ANEB, GTBP: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Phio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Shiller PE Ratio falls into.


PHIO
28GF Score
Phio Pharmaceuticals Corp PHIO
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Phio Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Phio Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.36/333.9520*333.9520
=-0.360

Current CPI (Jun. 2026) = 333.9520.

Phio Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -19,927.928 241.428 -27,565.036
201612 -20,247.706 241.432 -28,006.900
201703 -14,716.981 243.801 -20,158.922
201706 -6,429.668 244.955 -8,765.694
201709 -6,221.106 246.819 -8,417.305
201712 -4,894.866 246.524 -6,630.796
201803 -4,931.718 249.554 -6,599.602
201806 -2,589.918 251.989 -3,432.326
201809 -1,993.324 252.439 -2,636.972
201812 -593.994 251.233 -789.568
201903 -616.680 254.202 -810.149
201906 -498.960 256.143 -650.530
201909 -489.240 256.759 -636.327
201912 -507.021 256.974 -658.902
202003 -143.640 258.115 -185.843
202006 -36.720 257.797 -47.567
202009 -43.200 260.280 -55.428
202012 -44.280 260.474 -56.771
202103 -34.560 264.877 -43.573
202106 -21.600 271.696 -26.549
202109 -30.240 274.310 -36.815
202112 -27.585 278.802 -33.042
202203 -21.060 287.504 -24.462
202206 -19.980 296.311 -22.518
202209 -28.260 296.808 -31.797
202212 -21.600 296.797 -24.304
202303 -28.350 301.836 -31.367
202306 -13.269 305.109 -14.523
202309 -10.250 307.789 -11.121
202312 -1.480 306.746 -1.611
202403 -4.230 312.332 -4.523
202406 -3.620 314.175 -3.848
202409 -1.540 315.301 -1.631
202412 -0.850 315.605 -0.899
202503 -0.410 319.799 -0.428
202506 -0.450 322.561 -0.466
202509 -0.440 324.800 -0.452
202512 -0.204 324.054 -0.210
202603 -0.340 330.213 -0.344
202606 -0.360 333.952 -0.360

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Phio Pharmaceuticals Business Description

Address 411 Swedeland Road, Suite 23-1080, King of Prussia, PA, USA, 19406
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score

Get the complete analysis for PHIO

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.08
Price